Wegovy HD vs Standard Wegovy: Which Dose Is Right for You?

Wegovy HD vs Standard Wegovy: Which Dose Is Right for You?

The world of weight management is constantly evolving, and with the introduction of medications like Wegovy, many people have new questions about their treatment options. If you’ve heard about the new "high dose" or "HD" version of Wegovy, you might be wondering what it means for your health journey.

This guide provides a clear, practical look at the standard Wegovy dosing schedule versus the higher 7.2 mg dose (Wegovy HD), which the FDA approved on March 19, 2026. We'll break down what’s known, who the higher dose is for, and how you can have an informed conversation with your doctor about your treatment plan. Consult your healthcare provider before starting any medication.

Understanding Standard Wegovy Dosing

Wegovy (semaglutide) is a prescription injectable medication approved for chronic weight management in adults with obesity or who are overweight with at least one weight-related condition. It works by mimicking a gut hormone called GLP-1, which helps regulate appetite and food intake.

To ensure the body adapts to the medication and to minimize potential side effects, Wegovy is prescribed using a specific dose-escalation schedule.

The Titration Schedule

Patients typically start on a very low dose, which is gradually increased over several months. The standard, FDA-approved schedule looks like this:

• Weeks 1–4: 0.25 mg once weekly
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1.0 mg once weekly
• Weeks 13–16: 1.7 mg once weekly
• Week 17 and beyond: 2.4 mg (recommended) or 1.7 mg once weekly

If a dose step is not tolerated, the label says your doctor may consider delaying the next increase by 4 weeks.

This step-by-step increase is crucial. It gives your body time to get used to the medication, which can help manage common side effects like nausea, diarrhea, and constipation.

The Maintenance Dose

The final target dose of 2.4 mg is known as the maintenance dose. This is the dose that was studied extensively in the clinical trials (like the STEP program) that led to Wegovy’s approval for weight management. It remains the recommended maintenance dose for most people, including teenagers aged 12 and over.

What Is "Wegovy HD"?

Wegovy HD is the official name for the 7.2 mg dose of Wegovy injection, approved by the FDA on March 19, 2026. In the US it comes as a 7.2 mg single-dose pen. The 7.2 mg dose is also approved for adults with obesity in the EU and UK.

Under the US label, the dose may be increased to 7.2 mg once weekly for adults who have tolerated 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated. It is the maximum dose, it is not a starting dose, and it is not approved for adolescents.

Why a Higher Dose?

The reason for a higher dose is to offer greater weight loss for some adults who need more than the standard 2.4 mg dose provides. In medicine, many drugs have a "dose-response relationship," meaning that a higher dose can produce a stronger effect, and the trials were designed to test whether the extra benefit outweighs any increase in side effects.

The Evidence: Comparing Doses

To understand the difference, it helps to look at what the research says about the standard dose and what we’re learning about the higher doses under investigation.

Efficacy of Standard Wegovy (2.4 mg)

The clinical trials for the 2.4 mg dose of Wegovy were comprehensive and showed significant results. In the landmark STEP 1 trial, participants taking semaglutide 2.4 mg, combined with diet and exercise, lost an average of nearly 15% of their initial body weight over 68 weeks.

These results established Wegovy as an effective tool for weight management, but it's important to remember that this is an average. Individual results can and do vary based on many factors, including genetics, lifestyle, and adherence to the treatment plan.

Emerging Research on Higher Doses

The 7.2 mg dose was tested in the STEP UP trials:

• STEP UP (72 weeks, 1,407 adults with obesity without diabetes): average weight loss counting everyone was 18.7% with 7.2 mg, 15.6% with 2.4 mg and 3.9% with placebo. Among people who stayed on treatment, the 7.2 mg figure was 20.7%, and about 1 in 3 (31.2%) lost 25% or more.
• STEP UP T2D (72 weeks, adults with obesity and type 2 diabetes): average weight loss counting everyone was 13.2% with 7.2 mg, 10.4% with 2.4 mg and 3.8% with placebo. The FDA noted that blood sugar (HbA1c) fell by about the same amount as with the lower dose.

Whether the higher dose gives extra heart or other long-term benefits has not yet been shown.

Comparing Side Effects

The most common side effects of standard Wegovy are gastrointestinal, including nausea, vomiting, diarrhea, and constipation. These are most common during the dose-escalation phase and often improve over time.

Side effects were more common with the higher dose. In STEP UP, gastrointestinal side effects were reported by 70.8% on 7.2 mg, 61.2% on 2.4 mg and 42.8% on placebo. Altered skin sensation (dysaesthesia), such as tingling, burning or sensitivity, was reported by 22.9% on 7.2 mg versus 6.0% on 2.4 mg; the FDA said it usually resolved on its own or with dose reduction. Hair loss was also more common at 7.2 mg.

Both doses share the same serious warnings. Get urgent medical help for severe stomach pain that does not go away (it may spread to your back), pain in the upper right abdomen with fever or yellowing of the skin or eyes, signs of a serious allergic reaction, or vomiting or diarrhoea so severe you cannot keep fluids down. If you take insulin or a sulfonylurea, ask your doctor about low blood sugar. Wegovy carries a US boxed warning about thyroid C-cell tumours and must not be used if you or a close relative has had medullary thyroid carcinoma (MTC) or if you have MEN 2.

Which Dose Is Right for You?

This is the most important question, and the answer is unique to each individual. The decision about medication and dosage is a collaborative one made between you and your healthcare provider.

For most people, the standard schedule up to 2.4 mg (or 1.7 mg) remains the starting point. The 7.2 mg dose is an option your doctor may consider only after you have tolerated 2.4 mg for at least 4 weeks and if more weight loss is clinically needed. Do not increase your dose or combine pens yourself.

Your Discussion with Your Doctor

When you talk with your doctor about your progress on Wegovy, the conversation will likely revolve around two key factors:

• Efficacy: How is the medication working for you? Are you achieving meaningful weight loss and improvements in your health?
• Tolerability: How are you handling the side effects? Are they manageable, or are they impacting your quality of life?

Your provider will use this information to decide whether to stay at your current dose, move to 7.2 mg, or step down to a lower dose, within the approved label.

Making an Informed Decision

Navigating your weight management journey requires good information and a strong partnership with your healthcare team. While the prospect of new treatment options is encouraging, it’s essential to focus on the safe, effective, and approved options available today.

The standard Wegovy dosing schedule, with its gradual titration up to the 2.4 mg maintenance dose, is the evidence-backed path for those prescribed the medication, and Wegovy HD (7.2 mg) is an approved next step for some adults who need more. Your health decisions should always be grounded in the science we have now and made with your doctor.

Building a sustainable, healthy lifestyle is a long-term process, and having a trusted medical professional to guide you is key. Consult your healthcare provider before starting any medication.

Sources

1. Novo Nordisk. Wegovy US Prescribing Information (revised June 2026). https://www.novo-pi.com/wegovy.pdf
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
3. Wegovy (semaglutide) injection Official Website. Taking Wegovy. https://www.wegovy.com/taking-wegovy/dosing-schedule.html
4. ClinicalTrials.gov. Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity (STEP UP). https://clinicaltrials.gov/study/NCT05646706
5. European Medicines Agency (EMA). Wegovy (semaglutide) Overview. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
6. Wharton, S., et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes & Endocrinology. https://pubmed.ncbi.nlm.nih.gov/40961952/
7. Lingvay, I., et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D). Lancet Diabetes & Endocrinology. https://pubmed.ncbi.nlm.nih.gov/40961953/
8. U.S. Food and Drug Administration. FDA approves higher-dose semaglutide (19 March 2026). https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide
9. Novo Nordisk. Wegovy HD (semaglutide 7.2 mg) approved in the US (19 March 2026). https://www.biospace.com/press-releases/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss